Emergent BioSolutions
64
0
0
52
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
7.8%
5 terminated/withdrawn out of 64 trials
91.2%
+4.7% vs industry average
23%
15 trials in Phase 3/4
62%
32 of 52 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (64)
VELOCITY: An Anthrax Vaccine Clinical Study
Role: lead
Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults
Role: lead
Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax
Role: lead
A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients
Role: lead
Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax
Role: lead
Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario
Role: lead
BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients
Role: lead
Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.
Role: lead
VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection
Role: lead
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
Role: lead
Ciprofloxacin BioThrax Co-Administration Study
Role: lead
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
Role: lead
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
Role: lead
Study of SIAN Nasal Spray in Healthy Adults
Role: lead
Universal Influenza A Vaccine in Healthy Adults
Role: lead
Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
Role: lead
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
Role: collaborator
Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)
Role: collaborator
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
Role: collaborator
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
Role: lead